Aldo-Keto Reductase (AKR) 1C3 Inhibitors: A Patent Review
September 2017
in “
Expert opinion on therapeutic patents
”
Studysummary This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on europepmc.org →